SEC Form 4
GLOBUS MEDICAL INC (GMED) insider trading
In the 12 months to Oct 26, 2026, 7 GMED insiders reported open-market sales of $17.5M across 13 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $17.5M
- 13 filings · 7 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 8 of 13
- $6.8M of $17.5M sold (39%)
Who traded GMED, and when
- Sale
- Sale, pre-arranged (10b5-1)
GMED daily close from Oct 27, 2025 to Oct 26, 2026, between $60.39 and $96.82, last $81.83. 13 sale and 0 purchase filings by 7 insiders, marked at their filing dates. Stephen T. Zarrilli, Director: sold $4.3M across 2 filings, first filed Nov 13, 2025, last Aug 19, 2026. David D. Davidar, Director: sold $4.2M across 2 filings, first filed Nov 13, 2025, last Jun 9, 2026. Kelly Huller, SVP, GC, Corporate Secretary → EVP, GC, Corporate Secretary: sold $3.4M across 3 filings, first filed Nov 28, 2025, last Feb 27, 2026. James R. Tobin, Director: sold $2.2M across 1 filing, first filed Sep 16, 2026, last Sep 16, 2026. Kyle Kline, Senior Vice President, CFO: sold $2.0M across 2 filings, first filed Dec 3, 2025, last Jan 12, 2026. Ann D. Rhoads, Director: sold $818.0K across 1 filing, first filed Nov 10, 2025, last Nov 10, 2025. Leslie V. Norwalk, Director: sold $557.6K across 2 filings, first filed Dec 16, 2025, last Jan 12, 2026.
Largest mark · tap a row for others
James R. Tobin · Director
Sale $2,237,502
30,000 shares at $74.58 avg
Filed Sep 16, 2026 · traded Sep 15
Close on filing date $75.26
Stephen T. Zarrilli · Director
Director
$4.3M soldDavid D. Davidar · Director
Director
$4.2M soldKelly Huller · SVP, GC, Corporate Secretary → EVP, GC, Corporate Secretary
SVP, GC, Corporate Secretary → EVP, GC, Corporate Secretary
$3.4M soldJames R. Tobin · Director
Director
$2.2M soldKyle Kline · Senior Vice President, CFO
Senior Vice President, CFO
$2.0M soldAnn D. Rhoads · Director
Director
$818.0K soldLeslie V. Norwalk · Director
Director
$557.6K soldOpen-market trades
13 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Stephen T. Zarrilli | Director | $4.3M | — | 2 | — | |
| David D. Davidar | Director | $4.2M | — | 2 | — | |
| Kelly Huller | SVP, GC, Corporate Secretary → EVP, GC, Corporate Secretary | $3.4M | — | 3 | 100% of sales | |
| James R. Tobin | Director | $2.2M | — | 1 | — | |
| Kyle Kline | Senior Vice President, CFO | $2.0M | — | 2 | 100% of sales | |
| Ann D. Rhoads | Director | $818.0K | — | 1 | 100% of sales | |
| Leslie V. Norwalk | Director | $557.6K | — | 2 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | James R. Tobin Director | Sale | 30,000 | $74.58 | $2.2M | 0 | |
traded | Stephen T. Zarrilli Director | Sale | 25,000 | $87.04 | $2.2M | 0 | |
traded | David D. Davidar Director | Sale | 25,000 | $80.76 | $2.0M | 510,175 | |
traded | Kelly Huller EVP, GC, Corporate Secretary | SalePre-arranged (10b5-1) | 20,000 | $94.50 | $1.9M | 0 | |
traded | Kelly Huller EVP, GC, Corporate Secretary | SalePre-arranged (10b5-1) | 10,000 | $87.67 | $876.7K | 0 | |
traded | Leslie V. Norwalk Director | SalePre-arranged (10b5-1) | 2,000 | $101.10 | $202.2K | 10,419 | |
traded | Kyle Kline Senior Vice President, CFO | SalePre-arranged (10b5-1) | 3,594 | $101.10 | $363.4K | 0 | |
traded | Leslie V. Norwalk Director | SalePre-arranged (10b5-1) | 4,000 | $88.85 | $355.4K | 12,419 | |
traded | Kyle Kline Senior Vice President, CFO | SalePre-arranged (10b5-1) | 18,542 | $90.00 | $1.7M | 0 | |
traded | Kelly Huller SVP, GC, Corporate Secretary | SalePre-arranged (10b5-1) | 7,500 | $90.00 | $675.0K | 0 | |
traded | Stephen T. Zarrilli Director | Sale | 25,000 | $84.29 | $2.1M | 0 | |
traded | David D. Davidar Director | Sale | 25,000 | $86.00 | $2.2M | 516,275 | |
traded | Ann D. Rhoads Director | SalePre-arranged (10b5-1) | 10,000 | $81.80 | $818.0K | 15,384 |
GET /stocks/filings/vX/form-4?tickers=GMED&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"GMED"
],
"issuer_cik": "0001237831",
"owner_cik": "0001190128",
"accession_number": "0001193125-26-393147",
"form_type": "4",
"filing_date": "2026-09-16",
"period_of_report": "2026-09-15",
"issuer_name": "GLOBUS MEDICAL INC",
"issuer_trading_symbol": "GMED",
"owner_name": "TOBIN JAMES R",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-09-15",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 30000,
"transaction_price_per_share": 74.5834,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 0,
"transaction_value": 2237502,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.33 to $74.96, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."
}
]
},
{
"tickers": [
"GMED"
],
"issuer_cik": "0001237831",
"owner_cik": "0001203410",
"accession_number": "0001193125-26-357121",
"form_type": "4",
"filing_date": "2026-08-19",
"period_of_report": "2026-08-18",
"issuer_name": "GLOBUS MEDICAL INC",
"issuer_trading_symbol": "GMED",
"owner_name": "ZARRILLI STEPHEN T",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Class A Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": false,
"transaction_date": "2026-08-18",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 25000,
"transaction_price_per_share": 87.0386,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 0,
"transaction_value": 2175965,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.92 to $87.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 18 records
- Option exercises16 records
- Gifts2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has GLOBUS MEDICAL INC's CEO sold stock?
No. Keith W. Pfeil (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is GMED’s insider data?
These are GMED Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track GMED insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for GMED every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.